Supported by an unrestricted educational grant from AstraZeneca In this supplement to Oncology NEWS International, guest editor Aman U. Buzdar, MD, highlights key data presented at the December 2008 San Antonio Breast Cancer Symposium. In his in-depth commentary, Dr. Buzdar contextualizes these practice-changing study results and explains how the evolution of endocrine therapies has helped to change the natural history of early breast cancer and to prolong survival in metastatic disease.
Supported by an unrestricted educational grant from AstraZeneca
In this supplement to Oncology NEWS International, guest editor Aman U. Buzdar, MD, highlights key data presented at the December 2008 San Antonio Breast Cancer Symposium. In his in-depth commentary, Dr. Buzdar contextualizes these practice-changing study results and explains how the evolution of endocrine therapies has helped to change the natural history of early breast cancer and to prolong survival in metastatic disease.